Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
HOME > COLUMN
COLUMN
- A Peek into the Digital Pharmaceutical Industry
November 21, 2019
- Plant the Seeds of Success when Battling a Crisis
September 30, 2019
- Practice Makes Perfect - Even in Marketing!
August 19, 2019
- Failing Isn’t the Issue. What You Do Next Is All that Counts
July 26, 2019
- Big Question Mark to Pricey Drug Bashing
July 12, 2019
- The Science Behind Stage Fright, and How You Can Overcome It
June 28, 2019
- The Power in Teaching Your Team “How to Speak”
May 28, 2019
- Unlock Hidden Talent by Hiring for These Four Traits
May 10, 2019
- No Drug “Reviews” for 1st Time in 2 Years
April 22, 2019
- 6 Core Elements of Recruitment Mastery
March 22, 2019
- Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
February 27, 2019
- Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
- Expat Truths from the Japanese Medical Device World
December 3, 2018
- Why Did the Project Take so Long?
November 16, 2018
- Finding Captains in Your Organization
October 12, 2018
- Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
- How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
- Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources
July 20, 2018
- 5 Billion Yen Blockbuster?
June 20, 2018
- It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
ページ
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…